metsera glp 1 Metsera: An Emerging Contender In The GLP‑1 Arena (NASDAQ:MTSR) Metsera's obesity drug MET-233i drives
Pay in 4 interest-free payments of $7.36 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6















&srotate=0)











